Access Restriction

Author Kim, Sangmin ♦ Han, Jeonghun ♦ Jeon, Myeongjin ♦ You, Daeun ♦ Lee, Jeongmin ♦ Kim, Hee Jung ♦ Bae, Sarang ♦ Nam, Seok Jin ♦ Lee, Jeong Eon
Source SpringerLink
Content type Text
Publisher Springer Netherlands
File Format PDF
Copyright Year ©2016
Language English
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword Silibinin ♦ TGF-β2 ♦ Fibronectin ♦ MMP-2 ♦ MMP-9 ♦ Triple negative breast cancer ♦ Cancer Research
Abstract Transforming growth factor-beta (TGF-β) is a multifunctional cytokine that regulates many biological events including cell motility and angiogenesis. Here, we investigated the role of elevated TGF-β2 level in triple negative breast cancer (TNBC) cells and the inhibitory effect of silibinin on TGF-β2 action in TNBC cells. Breast cancer patients with high TGF-β2 expression have a poor prognosis. The levels of TGF-β2 expression increased significantly in TNBC cells compared with those in non-TNBC cells. In addition, cell motility-related genes such as fibronectin (FN) and matrix metalloproteinase-2 (MMP-2) expression also increased in TNBC cells. Basal FN, MMP-2, and MMP-9 expression levels decreased in response to LY2109761, a dual TGF-β receptor I/II inhibitor, in TNBC cells. TNBC cell migration also decreased in response to LY2109761. Furthermore, we observed that TGF-β2 augmented the FN, MMP-2, and MMP-9 expression levels in a time- and dose-dependent manner. In contrast, TGF-β2-induced FN, MMP-2, and MMP-9 expression levels decreased significantly in response to LY2109761. Interestingly, we found that silibinin decreased TGF-β2 mRNA expression level but not that of TGF-β1 in TNBC cells. Cell migration as well as basal FN and MMP-2 expression levels decreased in response to silibinin. Furthermore, silibinin significantly decreased TGF-β2-induced FN, MMP-2, and MMP-9 expression levels and suppressed the lung metastasis of TNBC cells. Taken together, these results suggest that silibinin suppresses metastatic potential of TNBC cells by inhibiting TGF-β2 expression in TNBC cells. Thus, silibinin may be a promising therapeutic drug to treat TNBC.
ISSN 10104283
Age Range 18 to 22 years ♦ above 22 year
Educational Use Research
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2016-03-16
Publisher Place Dordrecht
e-ISSN 14230380
Journal Tumor Biology
Volume Number 37
Issue Number 8
Page Count 11
Starting Page 11397
Ending Page 11407

Open content in new tab

   Open content in new tab
Source: SpringerLink